TCM
VIR icon

Tang Capital Management’s Vir Biotechnology VIR Stock Holding History

Tang Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$3.24M – 217
2025
Q1 		$3.24M Buy
+500,000
New +$4.45M 0.18% 97

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tang Capital Management's VIR Position: Q2 2025 in Review

Tang Capital Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 500,000 shares — an estimated $3.24M sold.

Tang Capital Management first reported a position in VIR in Q1 2025 and held it in 1 quarter. The position peaked at $3.24M in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Tang Capital Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Tang Capital Management sold 500,000 Vir Biotechnology shares in Q2 2025, an estimated $3.24M.
  • Tang Capital Management first reported a position in Vir Biotechnology in Q1 2025 and held it in 1 quarter.
  • Tang Capital Management's Vir Biotechnology position peaked at $3.24M in Q1 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.